These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31097113)

  • 21. Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the "sectioning and extensively examining the FIMbriated end" (SEE-FIM) protocol?
    Mahe E; Tang S; Deb P; Sur M; Lytwyn A; Daya D
    Int J Gynecol Pathol; 2013 Jul; 32(4):353-7. PubMed ID: 23722507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
    Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
    [No Abstract]   [Full Text] [Related]  

  • 23. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma.
    Kwon HJ; Song SY; Kim HS
    Anticancer Res; 2021 Mar; 41(3):1579-1586. PubMed ID: 33788752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
    Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
    Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
    Morency E; Leitao MM; Soslow RA
    Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
    Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
    Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development.
    Malmberg K; Klynning C; Flöter-Rådestad A; Carlson JW
    Virchows Arch; 2016 Jun; 468(6):707-13. PubMed ID: 27003156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
    Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
    Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases.
    Schneider S; Heikaus S; Harter P; Heitz F; Grimm C; Ataseven B; Prader S; Kurzeder C; Ebel T; Traut A; du Bois A
    Int J Gynecol Cancer; 2017 Mar; 27(3):444-451. PubMed ID: 28187099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.
    Soong TR; Howitt BE; Miron A; Horowitz NS; Campbell F; Feltmate CM; Muto MG; Berkowitz RS; Nucci MR; Xian W; Crum CP
    J Pathol; 2018 Nov; 246(3):344-351. PubMed ID: 30043522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-grade serous carcinoma of tubo-ovarian origin: recent developments.
    Singh N; McCluggage WG; Gilks CB
    Histopathology; 2017 Sep; 71(3):339-356. PubMed ID: 28477361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin.
    Bagby C; Ronnett BM; Yemelyanova A; Maleki Z; Kuhn E; Vang R
    Int J Gynecol Pathol; 2013 Sep; 32(5):433-43. PubMed ID: 23896706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer.
    Nishida N; Murakami F; Higaki K
    Pathol Int; 2016 Jun; 66(6):337-42. PubMed ID: 27250113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
    Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
    J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of the fallopian tube in ovarian cancer.
    Tone AA; Salvador S; Finlayson SJ; Tinker AV; Kwon JS; Lee CH; Cohen T; Ehlen T; Lee M; Carey MS; Heywood M; Pike J; Hoskins PJ; Stuart GC; Swenerton KD; Huntsman DG; Gilks CB; Miller DM; McAlpine JN
    Clin Adv Hematol Oncol; 2012 May; 10(5):296-306. PubMed ID: 22706539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: a pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer).
    Seidman JD
    Int J Gynecol Pathol; 2015 Mar; 34(2):112-20. PubMed ID: 25675178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-grade serous ovarian cancer: a unique disease.
    Schmeler KM; Gershenson DM
    Curr Oncol Rep; 2008 Nov; 10(6):519-23. PubMed ID: 18928667
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
    Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour morphology after neoadjuvant chemotherapy as a predictor of survival in serous ovarian cancer: an experience from a tertiary care centre in India.
    Khandakar B; Kumar L; Kumar S; Gupta SD; Kalaivani M; Iyer V; Mathur SR
    Malays J Pathol; 2015 Aug; 37(2):115-21. PubMed ID: 26277668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.